# Pasireotide (Signifor)

> Multi-receptor somatostatin analog for Cushing's disease and acromegaly.

Source: https://peptides.cafe/peptide/pasireotide
Category: Somatostatin Analog · Endocrine
Tag: FDA-Approved · Endocrine

## Mechanism
Cyclohexapeptide somatostatin analog binding somatostatin receptors SST1, 2, 3, and 5 (with highest affinity for SST5), suppressing ACTH in corticotroph adenomas and GH/IGF-1 in somatotroph tumors.

## Research areas
- Cushing's disease
- Acromegaly (LAR formulation)

## Common research protocols
- Cushing's (SC): 0.3–0.9 mg SC twice daily, titrated to cortisol response.
- Acromegaly (LAR IM): 20–60 mg IM every 28 days.

## Study summaries
- "Pasireotide in Cushing's disease (Phase III)" — NEJM (2012): Reduced urinary free cortisol with dose-dependent hyperglycemia.

## Considerations
- FDA-approved.
- Significant hyperglycemia risk requires glucose monitoring.
- Bradycardia and QT prolongation possible.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.